⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATAI News
Atai Beckley N.V Common Shares
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
globenewswire.com
ATAI
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
prnewswire.com
GHRS
HELP
DFTX
ATAI
CMPS
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
globenewswire.com
ATAI
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
globenewswire.com
ATAI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
prnewswire.com
GHRS
DFTX
HELP
ATAI
LBRX
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
globenewswire.com
ATAI
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
globenewswire.com
ATAI
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
globenewswire.com
ATAI
AtaiBeckley To Participate in Upcoming Investor Conferences
globenewswire.com
ATAI
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
globenewswire.com
ATAI
JNJ
BMY
NVS